Trust Co. of Oklahoma decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,016 shares of the company’s stock after selling 100 shares during the quarter. Trust Co. of Oklahoma’s holdings in Johnson & Johnson were worth $1,060,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. State Street Corp raised its holdings in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. Korea Investment CORP raised its holdings in Johnson & Johnson by 38.9% in the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after purchasing an additional 596,134 shares in the last quarter. Bank of Nova Scotia raised its holdings in Johnson & Johnson by 94.5% in the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in Johnson & Johnson in the first quarter worth $65,598,000. Finally, CIBC World Markets Inc. raised its holdings in Johnson & Johnson by 111.8% in the first quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after purchasing an additional 500,662 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.74 EPS.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.
A number of research firms have issued reports on JNJ. J P Morgan Chase & Co increased their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price objective for the company. in a report on Friday. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price objective (up previously from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, UBS AG restated a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $135.98.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.